Guardant Health, Inc. (NASDAQ:GH) on Thursday announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE) to support the ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” first quarter 2025 investor ...

Precision oncology company Guardant Health has announced a strategic collaboration with Pfizer to support the development and ...

Guardant Health (GH) announced a strategic collaboration with Pfizer (PFE) to support the development and commercialization of Pfizer’s ...

Also Read: Medicare To Reimburse Guardant Health’s Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue The collaboration will also allow Pfizer to access Guardant’s liquid biopsy ...

These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward ...

PALO ALTO, Calif. - Guardant Health, Inc. (NASDAQ: GH), a $5.6 billion market cap pioneer in precision oncology, has entered into a strategic collaboration with global pharmaceutical giant Pfizer ...

Guardant Health, Inc. (NASDAQ:GH – Free Report) – Analysts at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for shares of Guardant Health in a research report issued on ...

The full abstracts for Guardant Health and a list of all abstracts being presented at AACR 2025 can be found on the AACR website.